• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Size Matters When it Comes to Choosing The Right Stent

by Fred Pennic 09/16/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Size Matters When It Comes to Choosing The Right Stent

It doesn’t take long for kids to figure out that people come in all different shapes and sizes and that what differentiates us from one another is what makes us unique. And while we are told from a young age that we are all the same inside—that we all see, smell, taste, touch and hear the same as one another—there are nuances to this that become apparent as we age.

Our vasculature is a good case in point. While our arteries all carry blood to and from the heart, they are not all the same size. And when it comes to cardiovascular disease and the stents designed to treat it, size matters. That’s why Abbott has invested in the research and development of stents that not only vary in length but also vary based on the diameter of the vessels being treated.

The launch of the c in 4.5 & 5.0 mm sizes is the result of several new research and development initiatives. In order to make these expanded-size stents to treat larger vessels, Abbott leveraged its existing balloon technology to place the XIENCE™ stent platform on larger balloons. These medical devices then underwent rigorous testing to ensure safety and quality. Next, new manufacturing processes were implemented, which enabled product production at scale.

Why is this important?

The new sizes give physicians more choice and an option that didn’t exist before—and they increase the convenience for the physician, helping reduce the risk of complications when treating a 5.0-millimeter vessel. These means physicians can use the 5.0-millimeter stent diameter without the need to post-dilate.

There are other advantages to using this drug-eluting stent in a larger size—it is the only stent of it’s size that is indicated for high bleeding risk patients with 1-month and 3-month Dual Anti-Platelet Therapy (DAPT) labeling. 

At Abbott’s vascular business, our vision is to reduce the burden of vascular diseases for patients around the world by continuously improving our family of minimally invasive vascular technologies. Abbott’s tools give physicians the precision—and confidence they need to treat patients; to have visibility into arteries and remove blockages to help patients heal faster. The XIENCE™ Family of Stents is designed with unique attributes that make it an excellent choice for large vessels – this includes excellent longitudinal strength and features that allow it to be placed precisely in the location needed.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Abbott, Heal, Heart, Medical Devices, physicians, risk

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |